Head to head
Eli Lilly and Co vs Johnson & Johnson
Side-by-side on the measures that matter, with a plain-English read. Full detail: LLY · JNJ
LLY
Eli Lilly and Co
1,179.27+0.83%
1-year price shape — +39% over the period
Quant Rating B · 77/100
vs
JNJ
Johnson & Johnson
261.44+1.93%
1-year price shape — +40% over the period
Quant Rating B · 78/100
1-year performance, rebased to 100
Johnson & Johnson edges it on the scoreable measures. Johnson & Johnson has the highest Quant Rating (78); Johnson & Johnson has done best over the past year (+40%); Johnson & Johnson trades cheapest on trailing earnings.
| LLY | JNJ | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - General | -- |
| Last price | 1,179.27 | 261.44 |
| Change today | +0.83% | +1.93% |
| 1-year return | +38.7% | +39.9% |
| Market cap | $1.11T | $630.04B |
| 52-week range | 778.93 – 1,292.65 | 180.59 – 281.07 |
| Valuation | ||
| P/E (TTM) | 39.59 | 30.33 |
| P/E percentile, own 5-yr range | 6th | 85th |
| P/B | 32.77 | 7.41 |
| Dividend yield | 0.55% | 2.00% |
| Profitability & growth | ||
| EPS (TTM) | 22.95 | 11.03 |
| Net profit (TTM) | $21.60B | $26.58B |
| Revenue (TTM) | $79.67B | $97.93B |
| Revenue growth (YoY) | +47.7% | +6.6% |
| Gross margin | 83.4% | 67.9% |
| Operating margin | 49.7% | 26.8% |
| Net margin | 33.5% | 21.5% |
| Free cash flow (TTM) | $13.56B | $22.23B |
| Ownership & sentiment | ||
| Institutional ownership | 79.3% | 76.4% |
| Insider activity (12mo) | 37 buy / 13 sell | 27 buy / 20 sell |
| Short interest (% of float) | 0.7% | 0.9% |
| Analyst consensus | 91% buy / 5% hold / 5% sell (22) | 78% buy / 22% hold (18) |
| Analyst price target | $1,383 (+17%) | $290 (+11%) |
| StockVane view | ||
| StockVane Quant Rating | B (77) | B (78) |
| Company | ||
| Employees | 50,000 | 138,200 |
| Founded | 1876 | 1887 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.